罕见EGFR外显子19插入缺失变异对NSCLC靶向治疗疗效的影响
该回顾性研究筛选2467例初治NSCLC患者,经倾向评分匹配比较93例罕见EGFR 19delins与93例常见19del患者。罕见19delins患者一线EGFR-TKI的中位PFS显著更长(19.0 vs 13.0个月),但获得T790M后二线奥希替尼的mPFS显著更短(5.0 vs 12.0个月)。
要点
- 罕见EGFR 19delins患者一线EGFR-TKI的mPFS优于常见19del(19.0 vs 13.0个月)。
- 两组T790M获得率、小细胞转化率和MET扩增率相似。
- 罕见19delins患者T790M后二线奥希替尼mPFS更短(5.0 vs 12.0个月)。
核心结论
- 罕见EGFR 19delins患者一线第一代EGFR-TKI治疗临床结局更优,但发生T790M耐药后结局更差。
研究设计与样本
- 回顾性研究,筛查2015年1月至2018年8月2467例初治NSCLC患者的靶向测序数据。
- 经倾向评分1:1匹配,纳入93例罕见EGFR 19delins和93例常见EGFR 19del患者。
主要发现
- 鉴定出10种既往未报道的EGFR 19delins变异。
- L747_P753delinsS、L747_A750delinsP和E746_S752delinsV分别占33.1%(42/127)、23.6%(30/127)和12.6%(16/127)。
- 罕见19delins组mPFS为19.0个月,常见19del组为13.0个月(p=0.0016)。
- 进展时两组T790M获得率(45.8% vs 57.8%)、小细胞转化(3.4% vs 3.6%)和MET扩增(5.1% vs 4.8%)相似。
- T790M后二线奥希替尼的mPFS在罕见19delins组(n=27)为5.0个月,常见19del组(n=47)为12.0个月(p<0.0001)。
临床怎么用
- 对罕见EGFR 19delins患者,一线可考虑第一代EGFR-TKI治疗。
- 罕见19delins患者出现T790M后接受奥希替尼的获益可能有限,需密切监测。
局限性
- 回顾性研究设计。
- 罕见19delins亚组样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Our study aimed to evaluate the efficacy and resistance mechanisms of first-line epidermal growth factor receptor (EGFR) inhibitor therapy in patients with advanced non-small-cell lung cancer (NSCLC) harbouring uncommon EGFR exon 19 deletion-insertion (19delins) variants. METHODS: Targeted sequencing data of 2467 treatment-naive patients with NSCLC from January 2015 to August 2018 were retrospectively screened for EGFR exon 19 deletion (19del) variants. Clinical outcomes of 93 patients with uncommon EGFR 19delins and 93 patients with common EGFR 19del were selected through propensity score matching at a ratio of 1:1. RESULTS: We identified 10 previously unreported EGFR 19delins variants. L747_P753delinsS, L747_A750delinsP and E746_S752delinsV were the most frequent variants, accounting for 33.1% (42/127), 23.6% (30/127) and 12.6% (16/127) of the cases, respectively. Despite similar baseline characteristics, treatment history and response rates, patients with uncommon 19delins had significantly longer median progression-free survival (mPFS) than those with common 19del (19.0 months vs. 13.0 months; p = 0.0016). At progression from first-line EGFR inhibitor therapy, patients with uncommon 19delins and common 19del had similar rates of developing resistance mechanisms including the acquisition of EGFR T790M (45.8% vs 57.8%), small-cell transformation (3.4% vs 3.6%) and MET amplification (5.1% vs 4.8%). For patients whose tumours acquired T790M and who received second-line osimertinib, the mPFS was significantly shorter for patients with uncommon 19delins (n = 27) than those with common 19del (n = 47, 5.0 months vs. 12.0 months; p < 0.0001). CONCLUSION: Our results suggest that patients with uncommon EGFR 19delins have improved clinical outcomes with first-generation EGFR inhibitor treatment, but inferior outcomes upon the development of T790M resistance mutations.
引用
- Peng X, Long X, Liu L, et al. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. Eur J Cancer. 2020. PMID: 33171317. doi:10.1016/j.ejca.2020.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。